Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | NQO1 | P15559 | 2/20 | 0.39 |
| ▸ | POR | P16435 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3327389 | 0.85 | STAT3 (0.50) | STAT3KDM4EALDH1A1HSD17B10NQO1 | |
| SCHEMBL29135593 | 0.83 | STAT3 (0.60) | STAT3KDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL29199282 | 0.83 | STAT3 (0.67) | STAT3KDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL3334136 | 0.82 | STAT3 (0.43) | STAT3KDM4EALDH1A1HSD17B10MAOB | |
| SCHEMBL3327381 | 0.81 | DNMT1 (0.50) | STAT3KDM4EALDH1A1HSD17B10MAOB | |
| SCHEMBL8197108 | 0.73 | TCF4 (0.57) | STAT3KDM4EALDH1A1HSD17B10NQO1 | |
| SCHEMBL3330784 | 0.70 | STAT3 (0.43) | STAT3KDM4EALDH1A1HSD17B10MAOB | |
| SCHEMBL8047458 | 0.70 | DNMT1 (0.40) | STAT3KDM4EALDH1A1HSD17B10MAOB | |
| SCHEMBL29135718 | 0.69 | STAT3 (0.53) | STAT3KDM4EALDH1A1CLK1DYRK1A | |
| SCHEMBL28578515 | 0.69 | KCNJ1 (0.52) | KDM4EALDH1A1CLK1DYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404869-B2 | Phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome | MAZENCE INC. (KR) | 2013-03-26 | — | — | US | claimed |
| US-20100137422-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | YUNGJIN PHARM. CO., LTD. (KR) | 2010-06-03 | — | — | US | claimed |
| EP-2137175-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | Mazence Inc. (KR) | 2009-12-30 | — | — | EP | claimed |
| WO-2008133441-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | MAZENCE INC. (KR) | 2008-11-06 | — | — | WO | claimed |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| EP-4180034-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO Ltd. (KR) | 2023-05-17 | — | — | EP | disclosed |
| US-20140154319-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | KWAK TAEHWAN (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20140154319-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | KWAK TAEHWAN (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20130302422-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES | KT & G CORPORATION (KR) | 2013-11-14 | — | — | US | disclosed |
| US-20130302422-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES | KT & G CORPORATION (KR) | 2013-11-14 | — | — | US | disclosed |
| US-20120289577-A1 | COMPOSITION FOR TREATING OR PREVENTING HEARING LOSS COMPRISING NAPHTHOQUINONE-BASED COMPOUNDS | KT&G LIFE SCIENCES CORPORATION (KR) | 2012-11-15 | — | — | US | disclosed |
| WO-2009084834-A2 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | MAZENCE INC. (KR) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009048251-A2 | PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED PARTICLES OF NAPHTHOQUINONE-BASED COMPOUND | MAZENCE INC. (KR) | 2009-04-16 | — | — | WO | disclosed |
| WO-2008133441-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | MAZENCE INC. (KR) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008066294-A1 | PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED PARTICLE OF NAPHTHOQUINONE-BASED COMPOUND | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066301-A1 | ANTICANCER COMPOSITION CONTAINING NAPHTHOQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066298-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF PROSTATE-RELATED DISEASES AND PHARMACEUTICAL COMPOSITION OF COLON DELIVERY SYSTEM CONTAINING THE SAME | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066299-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066296-A1 | PHARMACEUTICAL COMPOSITION CONTAINING PHENANTHRENEQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302422-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES | REN, ATP6V1B1, SLC5A1 | STAT3 3921/4885KDM4E 4046/4885ALDH1A1 1237/4885 |
| US-20120289577-A1 | COMPOSITION FOR TREATING OR PREVENTING HEARING LOSS COMPRISING NAPHTHOQUINONE-BASED COMPOUNDS | NQO1, MT-ND6, MT-ND5 | STAT3 4645/4885KDM4E 3804/4885ALDH1A1 792/4885 |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | PDCD1, CD274, PDCD10 | STAT3 1876/4885KDM4E 3868/4885ALDH1A1 2536/4885 |
| US-20140154319-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | TNNT2, TNNC1, TNNI3 | STAT3 3416/4885KDM4E 4687/4885ALDH1A1 842/4885 |
| US-20100137422-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | CYP27A1, CYP46A1, PCSK9 | STAT3 2974/4885KDM4E 3921/4885ALDH1A1 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.